Pueraria lobata
PreclinicalSmall molecule
Pueraria lobata is one of 38 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Tanzeum
GSKPreclinical
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Dostinex
PfizerPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Golytely
BayerPreclinical
Lantus
SanofiPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Glargine
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pueraria lobata. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details